Phase II open label trial of imatinib in polycythemia rubra vera.

Abstract

Polycythemia rubra vera is a chronic myeloproliferative disorder characterized by panmyelosis with the resultant potential for thrombosis, myelofibrosis, and acute leukemia. Treatment has rested on phlebotomy and hydroxyurea. In 2002, we reported two patients who were unable to tolerate hydroxyurea but responded to imatinib mesylate (Gleevec). These… (More)
DOI: 10.1007/s12185-008-0193-1

Topics

4 Figures and Tables